186 related articles for article (PubMed ID: 11591778)
1. IL-2 during in vitro priming promotes subsequent engraftment and successful adoptive tumor immunotherapy by persistent memory phenotypic CD8(+) T cells.
Bathe OF; Dalyot-Herman N; Malek TR
J Immunol; 2001 Oct; 167(8):4511-7. PubMed ID: 11591778
[TBL] [Abstract][Full Text] [Related]
2. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment.
Bathe OF; Dalyot-Herman N; Malek TR
BMC Cancer; 2003 Jul; 3():21. PubMed ID: 12882650
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
Wang LX; Chen BG; Plautz GE
J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
[TBL] [Abstract][Full Text] [Related]
6. Effective anti-tumor adoptive immunotherapy: utilization of exogenous IL-2-independent cytotoxic T lymphocyte clones.
Iwashiro M; Jinyan W; Toda M; Linan W; Kato T; Kuribayashi K
Int Immunol; 2002 Dec; 14(12):1459-68. PubMed ID: 12456594
[TBL] [Abstract][Full Text] [Related]
7. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
8. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
9. Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy.
Wang LX; Kjaergaard J; Cohen PA; Shu S; Plautz GE
J Immunol; 2004 Mar; 172(6):3462-8. PubMed ID: 15004146
[TBL] [Abstract][Full Text] [Related]
10. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
11. The dual role of IL-2 in the generation and maintenance of CD8+ memory T cells.
Dai Z; Konieczny BT; Lakkis FG
J Immunol; 2000 Sep; 165(6):3031-6. PubMed ID: 10975812
[TBL] [Abstract][Full Text] [Related]
12. Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis.
Shrikant P; Mescher MF
J Immunol; 2002 Aug; 169(4):1753-9. PubMed ID: 12165496
[TBL] [Abstract][Full Text] [Related]
13. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
14. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen.
Ohlén C; Kalos M; Hong DJ; Shur AC; Greenberg PD
J Immunol; 2001 Feb; 166(4):2863-70. PubMed ID: 11160355
[TBL] [Abstract][Full Text] [Related]
15. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.
Chakraborty M; Abrams SI; Camphausen K; Liu K; Scott T; Coleman CN; Hodge JW
J Immunol; 2003 Jun; 170(12):6338-47. PubMed ID: 12794167
[TBL] [Abstract][Full Text] [Related]
16. Adoptive cell therapy using PD-1
Jing W; Gershan JA; Blitzer GC; Palen K; Weber J; McOlash L; Riese M; Johnson BD
J Immunother Cancer; 2017; 5():51. PubMed ID: 28642819
[TBL] [Abstract][Full Text] [Related]
17. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
18. TLR2 engagement on memory CD8(+) T cells improves their cytokine-mediated proliferation and IFN-gamma secretion in the absence of Ag.
Cottalorda A; Mercier BC; Mbitikon-Kobo FM; Arpin C; Teoh DY; McMichael A; Marvel J; Bonnefoy-Bérard N
Eur J Immunol; 2009 Oct; 39(10):2673-81. PubMed ID: 19634192
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.
Huarte E; Fisher J; Turk MJ; Mellinger D; Foster C; Wolf B; Meehan KR; Fadul CE; Ernstoff MS
Cancer Lett; 2009 Nov; 285(1):80-8. PubMed ID: 19501956
[TBL] [Abstract][Full Text] [Related]
20. Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}.
Cheng ML; Chen HW; Tsai JP; Lee YP; Shih YC; Chang CM; Ting CC
J Leukoc Biol; 2006 May; 79(5):1033-42. PubMed ID: 16478921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
